ViewRay (NASDAQ:VRAY) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of ViewRay (NASDAQ:VRAY – Get Rating) in a report released on Thursday. The brokerage issued a sell rating on the stock.

A number of other equities research analysts have also recently commented on VRAY. Oppenheimer reiterated an outperform rating and issued a $8.00 price target on shares of ViewRay in a research note on Tuesday, February 28th. Morgan Stanley increased their price target on ViewRay from $5.00 to $5.50 and gave the company an equal weight rating in a research note on Friday, November 18th. Finally, B. Riley restated a buy rating on shares of ViewRay in a research note on Thursday, November 17th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, ViewRay has a consensus rating of Moderate Buy and an average price target of $6.75.

ViewRay Stock Down 1.9 %

ViewRay stock opened at $3.55 on Thursday. The stock has a 50-day moving average of $4.40 and a two-hundred day moving average of $4.26. The company has a current ratio of 2.36, a quick ratio of 2.04 and a debt-to-equity ratio of 0.95. ViewRay has a one year low of $2.39 and a one year high of $4.96.

ViewRay (NASDAQ:VRAY – Get Rating) last released its quarterly earnings results on Monday, February 27th. The company reported ($0.15) EPS for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.01. ViewRay had a negative return on equity of 93.57% and a negative net margin of 105.01%. The company had revenue of $34.70 million during the quarter, compared to analysts’ expectations of $34.65 million. During the same period last year, the business posted ($0.16) earnings per share. The firm’s revenue was up 70.1% compared to the same quarter last year. Equities research analysts forecast that ViewRay will post -0.6 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Advisory Research Inc. raised its stake in shares of ViewRay by 3,537.7% in the third quarter. Advisory Research Inc. now owns 443,584 shares of the company’s stock worth $1,614,000 after purchasing an additional 431,390 shares during the last quarter. New York State Common Retirement Fund raised its position in ViewRay by 1.0% during the third quarter. New York State Common Retirement Fund now owns 742,596 shares of the company’s stock valued at $2,703,000 after acquiring an additional 7,399 shares in the last quarter. Needham Investment Management LLC raised its position in ViewRay by 1.4% during the second quarter. Needham Investment Management LLC now owns 2,549,080 shares of the company’s stock valued at $6,755,000 after acquiring an additional 34,580 shares in the last quarter. Perkins Capital Management Inc. raised its position in ViewRay by 14.9% during the third quarter. Perkins Capital Management Inc. now owns 50,000 shares of the company’s stock valued at $182,000 after acquiring an additional 6,500 shares in the last quarter. Finally, MetLife Investment Management LLC raised its position in ViewRay by 55.5% during the third quarter. MetLife Investment Management LLC now owns 80,040 shares of the company’s stock valued at $291,000 after acquiring an additional 28,583 shares in the last quarter. 84.40% of the stock is currently owned by hedge funds and other institutional investors.

ViewRay Company Profile

(Get Rating)

ViewRay, Inc designs, manufactures and markets magnetic resonance imaging (MRI) system. It develops MRIdian to address the limitations of existing external-beam radiation therapy technologies, and employs MRI-based technology to provide real-time imaging that defines the tumor from the surrounding soft tissue, and other critical organs, both before and during radiation treatment delivery.